{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:16:49Z","timestamp":1771013809403,"version":"3.50.1"},"reference-count":29,"publisher":"BMJ","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Fam Plann Reprod Health Care"],"accepted":{"date-parts":[[2005,2,1]]},"published-print":{"date-parts":[[2005,7]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Studies from the USA have suggested the feasibility and acceptability of home medical abortion, however the issue has not been addressed in the UK. This study aimed to assess the feasibility, efficacy and acceptability of home self-administration of misoprostol for medical abortion up to 56 days' gestation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Mifepristone 200 mg was given orally in hospital under nursing supervision. Women were provided with misoprostol tablets 600 \u03bcg and advised to take them sublingually 36\u201348 hours later. The main outcome measures were (1) feasibility, assessed through successful completion of abortion at home without the need for hospital admission, (2) efficacy, assessed through complete uterine evacuation without the need for further medical or surgical intervention and (3) women's acceptability of the procedure as assessed by questionnaire.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 49 women participated in this study. Of these, 48 women aborted at home while one opted to be admitted to hospital after receiving misoprostol at home. One woman underwent surgical evacuation 5 weeks following abortion for excessive bleeding and retained products of conception. A total of 43\/44 (98%) women were satisfied with having the abortion at home. Side effects experienced by women included nausea [32\/40 (80%], vomiting [17\/41 (42%)], diarrhoea [17\/41 (42%)], shivering [26\/40 (65%)], tiredness [32\/40 (80%)], headache [12\/39 (31%)], hot flushes [14\/40 (35%)], dizziness [24\/39 (62%)] and unpleasant mouth taste [19\/38 (50%)].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study suggests the feasibility and acceptability of home self-administration of misoprostol for medical abortion up to 56 days' gestation. These findings need to be assessed in the context of a randomised trial.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1783\/1471189054483915","type":"journal-article","created":{"date-parts":[[2005,7,19]],"date-time":"2005-07-19T11:04:00Z","timestamp":1121771040000},"page":"189-192","source":"Crossref","is-referenced-by-count":19,"title":["Home self-administration of misoprostol for medical abortion up to 56 days' gestation"],"prefix":"10.1136","volume":"31","author":[{"given":"Haitham","family":"Hamoda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Premila W","family":"Ashok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian M M","family":"Flett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan","family":"Templeton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2005,7,1]]},"reference":[{"key":"ref_1","author":"Department of Health. Abortion Statistics, England and Wales","year":"2002","unstructured":"Department of Health. Abortion Statistics, England and Wales, 2002. Department of Health Bulletin 2003\/23. London, UK: Department of Health, 2003.","journal-title":"Department of Health Bulletin"},{"key":"ref_2","article-title":"Abortion Statistics in Scotland 2002. ISD Scotland Health Briefing","author":"Information and Statistics Division (ISD","year":"2003","unstructured":"Information and Statistics Division (ISD). Abortion Statistics in Scotland 2002. ISD Scotland Health Briefing. Edinburgh, UK: Information and Statistics Division, 2003."},{"key":"ref_3","first-page":"353","article-title":"Vaginal misoprostol administered at home after mifepristone (RU486) for abortion","volume":"44","author":"Schaff, E.A.; Stadalius, L.S.; Eisinger, S.H.; Franks, P.","year":"1997","unstructured":"Schaff EA, Stadalius LS, Eisinger SH, Franks P. Vaginal misoprostol administered at home after mifepristone (RU486) for abortion. J Fam Pract 1997; 44: 353\u2013360.","journal-title":"J Fam Pract"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1001\/jama.284.15.1948","article-title":"Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a randomized trial","volume":"284","author":"Schaff, E.A.; Fielding, S.L.; Westhoff, C.; Ellertson, C.; Eisinger, S.H.; Stadalius, L.S.","year":"2000","unstructured":"Schaff EA, Fielding SL, Westhoff C, Ellertson C, Eisinger SH, Stadalius LS, et al. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a randomized trial. JAMA 2000; 284: 1948\u20131953.","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0010-7824(99)00119-5","article-title":"Lowdose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days","volume":"61","author":"Schaff, E.A.; Fielding, S.L.; Eisinger, S.H.; Stadalius, L.S.; Fuller, L.","year":"2000","unstructured":"Schaff EA, Fielding SL, Eisinger SH, Stadalius LS, Fuller L. Lowdose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days. Contraception 2000; 61: 41\u201346.","journal-title":"Contraception"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0010-7824(98)00150-4","article-title":"and vaginal misoprostol for abortion","volume":"59","author":"Schaff, E.A.; Eisinger, S.H.; Stadalius, L.S.; Franks, P.; Gore, B.Z.; Poppema, S.","year":"1999","unstructured":"Schaff EA, Eisinger SH, Stadalius LS, Franks P, Gore BZ, Poppema S. Low-dose mifepristone 200 mg and vaginal misoprostol for abortion. Contraception 1999; 59: 1\u20136.","journal-title":"Contraception"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0010-7824(01)00228-1","article-title":"Mifepristone followed on the same day by vaginal misoprostol for early abortion","volume":"64","author":"Pymar, H.C.; Creinin, M.D.; Schwartz, J.L.","year":"2001","unstructured":"Pymar HC, Creinin MD, Schwartz JL. Mifepristone followed on the same day by vaginal misoprostol for early abortion. Contraception 2001; 64: 87\u201392.","journal-title":"Contraception"},{"issue":"5883","key":"ref_8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/bmj.4.5883.28","article-title":"Sonar measurement of fetal crown\u2013rump length as means of assessing maturity in the first trimester of pregnancy","volume":"4","author":"Robinson, H.P.","year":"1973","unstructured":"Robinson HP. Sonar measurement of fetal crown\u2013rump length as means of assessing maturity in the first trimester of pregnancy. BMJ 1973; 4(5883): 28\u201331.","journal-title":"BMJ"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1471-0528.2004.00538.x","article-title":"The acceptability of home medical abortion to women in UK settings","volume":"112","author":"Hamoda, H.; Critchley, H.O.D.; Paterson, K.; Guthrie, K.; Rodger, M.; Penney, G.C.","year":"2005","unstructured":"Hamoda H, Critchley HOD, Paterson K, Guthrie K, Rodger M, Penney GC. The acceptability of home medical abortion to women in UK settings. Br J Obstet Gynaecol 2005; 112: 781\u2013785.","journal-title":"Br J Obstet Gynaecol"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1056\/NEJM199804303381801","article-title":"Early pregnancy termination with mifepristone and misoprostol in the United States","volume":"338","author":"Spitz, I.M.; Bardin, C.W.; Benton, L.; Robbins, A.","year":"1998","unstructured":"Spitz IM, Bardin CW, Benton L, Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med 1998; 338: 1241\u20131247.","journal-title":"N Engl J Med"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0010-7824(00)00187-6","article-title":"Parity is a major determinant of success rate in medical abortion: a retrospective analysis of 3161 consecutive cases of early medical abortion treated with reduced doses of mifepristone and vaginal gemeprost","volume":"62","author":"Bartley, J.; Tong, S.; Everington, D.; Baird, D.T.","year":"2000","unstructured":"Bartley J, Tong S, Everington D, Baird DT. Parity is a major determinant of success rate in medical abortion: a retrospective analysis of 3161 consecutive cases of early medical abortion treated with reduced doses of mifepristone and vaginal gemeprost. Contraception 2000; 62: 297\u2013303.","journal-title":"Contraception"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1046\/j.1471-0528.2002.02156.x","article-title":"Factors affecting the outcome of early medical abortion: a review of 4132 consecutive cases","volume":"109","author":"Ashok, P.W.; Templeton, A.; Wagaarachchi, P.T.; Flett, G.M.","year":"2002","unstructured":"Ashok PW, Templeton A, Wagaarachchi PT, Flett GM. Factors affecting the outcome of early medical abortion: a review of 4132 consecutive cases. Br J Obstet Gynaecol 2002; 109: 1281\u20131289.","journal-title":"Br J Obstet Gynaecol"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/humrep\/17.1.92","article-title":"A randomized comparison of medical abortion and surgical vacuum aspiration at 10\u201313 weeks\u2019","volume":"17","author":"Ashok, P.W.; Kidd, A.; Flett, G.M.; Fitzmaurice, A.; Graham, W.; Templeton, A.","year":"2002","unstructured":"Ashok PW, Kidd A, Flett GM, Fitzmaurice A, Graham W, Templeton A. A randomized comparison of medical abortion and surgical vacuum aspiration at 10\u201313 weeks\u2019 gestation. Hum Reprod 2002; 17: 92\u201398.","journal-title":"gestation. Hum Reprod"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.contraception.2003.09.006","article-title":"Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases","volume":"69","author":"Ashok, P.W.; Templeton, A.; Wagaarachchi, P.T.; Flett, G.M.M.","year":"2004","unstructured":"Ashok PW, Templeton A, Wagaarachchi PT, Flett GMM. Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases. Contraception 2004; 69: 51\u201358.","journal-title":"Contraception"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1093\/oxfordjournals.humrep.a138412","article-title":"A comparison of medical abortion (using mifepristone and gemeprost) with surgical vacuum aspiration: efficacy and early medical sequelae","volume":"9","author":"Henshaw, R.C.; Naji, S.A.; Russell, I.T.; Templeton, A.A.","year":"1994","unstructured":"Henshaw RC, Naji SA, Russell IT, Templeton AA. A comparison of medical abortion (using mifepristone and gemeprost) with surgical vacuum aspiration: efficacy and early medical sequelae. Hum Reprod 1994; 9: 2167\u20132172.","journal-title":"Hum Reprod"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3109\/00016349409072511","article-title":"Psychological responses following medical abortion (using mifepristone and gemeprost) and surgical vacuum aspiration. A patient-centered, partially randomised prospective study","volume":"73","author":"Henshaw, R.; Naji, S.; Russell, I.; Templeton, A.","year":"1994","unstructured":"Henshaw R, Naji S, Russell I, Templeton A. Psychological responses following medical abortion (using mifepristone and gemeprost) and surgical vacuum aspiration. A patient-centered, partially randomised prospective study. Acta Obstet Gynecol Scand 1994; 73: 812\u2013818.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/j.1471-0528.2004.00235.x","article-title":"Analgesia requirements and predictors of analgesia use for women undergoing medical abortion up to 22 weeks of gestation","volume":"111","author":"Hamoda, H.; Ashok, P.W.; Flett, G.M.; Templeton, A.","year":"2004","unstructured":"Hamoda H, Ashok PW, Flett GM, Templeton A. Analgesia requirements and predictors of analgesia use for women undergoing medical abortion up to 22 weeks of gestation. Br J Obstet Gynaecol 2004; 111: 996\u20131000.","journal-title":"Br J Obstet Gynaecol"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1471-0528.1997.tb12028.x","article-title":"Medical abortion or vacuum aspiration? Two year follow up of a patient preference trial","volume":"104","year":"1997","unstructured":"Medical abortion or vacuum aspiration? Two year follow up of a patient preference trial. Br J Obstet Gynaecol 1997; 104: 829\u2013833.","journal-title":"Br J Obstet Gynaecol"},{"issue":"3","key":"ref_19","first-page":"169","article-title":"In-depth interviews with medical abortion clients: thoughts on the method and home administration of misoprostol","volume":"55","author":"Elul, B.; Pearlman, E.; Sorhaindo, A.; Simonds, W.; Westhoff, C.","year":"2000","unstructured":"Elul B, Pearlman E, Sorhaindo A, Simonds W, Westhoff C. In-depth interviews with medical abortion clients: thoughts on the method and home administration of misoprostol. J Am Med Womens Assoc 2000; 55(3 Suppl.): 169\u2013172.","journal-title":"J Am Med Womens Assoc"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2307\/3030230","article-title":"Having an abortion using mifepristone and home misoprostol: a qualitative analysis of women\u2019s experiences","volume":"34","author":"Fielding, S.L.; Edmunds, E.; Schaff, E.A.","year":"2002","unstructured":"Fielding SL, Edmunds E, Schaff EA. Having an abortion using mifepristone and home misoprostol: a qualitative analysis of women\u2019s experiences. Perspect Sex Reprod Health 2002; 34: 34\u201340.","journal-title":"Perspect Sex Reprod Health"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJM199504133321502","article-title":"Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol","volume":"332","author":"H, El Refaey; D, Rajasekar; M, Abdalla; L, Calder; A, Templeton","year":"1995","unstructured":"El Refaey H, Rajasekar D, Abdalla M, Calder L, Templeton A. Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. N Engl J Med 1995; 332: 983\u2013987.","journal-title":"N Engl J Med"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0029-7844(97)00419-5","article-title":"Vaginal misoprostol compared with oral misoprostol in termination of second-trimester pregnancy","volume":"90","author":"Ho, P.C.; Ngai, S.W.; Liu, K.L.; Wong, G.C.; Lee, S.W.","year":"1997","unstructured":"Ho PC, Ngai SW, Liu KL, Wong GC, Lee SW. Vaginal misoprostol compared with oral misoprostol in termination of second-trimester pregnancy. Obstet Gynecol 1997; 90: 735\u2013738.","journal-title":"Obstet Gynecol"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0010-7824(01)00261-X","article-title":"Pilot study on the use of sublingual misoprostol for medical abortion","volume":"64","author":"Tang, O.S.; Ho, P.C.","year":"2001","unstructured":"Tang OS, Ho PC. Pilot study on the use of sublingual misoprostol for medical abortion. Contraception 2001; 64: 315\u2013317.","journal-title":"Contraception"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/humrep\/deg475","article-title":"A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks\u2019","volume":"18","author":"Tang OS, Chan CC, Ng EH, Lee SW, Ho PC","year":"2003","unstructured":"Tang OS, Chan CC, Ng EH, Lee SW, Ho PC. A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks\u2019 gestation. Hum Reprod 2003; 18: 2315\u20132318.","journal-title":"gestation. Hum Reprod"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.contraception.2003.07.004","article-title":"A pilot study of mifepristone in combination with sublingual or vaginal misoprostol for medical termination of pregnancy up to 63 days\u2019","volume":"68","author":"Hamoda, H.; Ashok, P.W.; Dow, J.; Flett, G.M.M.; Templeton, A.","year":"2003","unstructured":"Hamoda H, Ashok PW, Dow J, Flett GMM, Templeton A. A pilot study of mifepristone in combination with sublingual or vaginal misoprostol for medical termination of pregnancy up to 63 days\u2019 gestation. Contraception 2003; 68: 335\u2013338.","journal-title":"gestation. Contraception"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/01443610410001645451","article-title":"Self-administration of misoprostol for termination of pregnancy: safety and efficacy","volume":"24","author":"Kiran, U.; Amin, P.; Penketh, R.J.","year":"2004","unstructured":"Kiran U, Amin P, Penketh RJ. Self-administration of misoprostol for termination of pregnancy: safety and efficacy. J Obstet Gynaecol 2004; 24: 155\u2013156.","journal-title":"J Obstet Gynaecol"},{"key":"ref_27","year":"2004","unstructured":"London, UK: RCOG Press, 2004."},{"issue":"0","key":"ref_28","article-title":"Book Reviews Female Reproductive Health. N Manassiev and MI Whitehead","volume":"491","author":"1","year":"2003","unstructured":"Book Reviews Female Reproductive Health. N Manassiev and MI Whitehead. New York, NY: Parthenon Publishing Group, 2003. ISBN: 1 85070 491 0. Price: \u00a355.00. Pages: 195 (hardback)"},{"key":"ref_29","first-page":"9","article-title":"Jaffe\u2019s Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Managementn). JF Strauss III and RL Barbieri (eds)","volume":"9546","author":"and, Yen","year":"2004","unstructured":"Yen and Jaffe\u2019s Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management (5th edn). JF Strauss III and RL Barbieri (eds). Philadelphia, PA: Elsevier Saunders, 2004. ISBN: 0 7216 9546 9. Price: \u00a3117.00. Pages 1042 (hardback)","edition":"5"}],"container-title":["Journal of Family Planning and Reproductive Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1783\/1471189054483915","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T05:04:20Z","timestamp":1756875860000},"score":1,"resource":{"primary":{"URL":"https:\/\/jfprhc.bmj.com\/lookup\/doi\/10.1783\/1471189054483915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2005,7,1]]},"published-print":{"date-parts":[[2005,7]]}},"alternative-id":["10.1783\/1471189054483915"],"URL":"https:\/\/doi.org\/10.1783\/1471189054483915","relation":{},"ISSN":["1471-1893","2045-2098"],"issn-type":[{"value":"1471-1893","type":"print"},{"value":"2045-2098","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}